TRANSGENIC GROUP INC.'s stock price is ¥256, unchanged from the previous day, with after-hours PTS information also provided. According to the earnings report summary, revenue for the first quarter of the fiscal year ending March 2027 grew by more than 14% year on year, while operating income and net income also increased significantly. The full-year forecast remains unchanged.
(1) As an overview of the stock price and after-hours PTS information, TRANSGENIC GROUP INC.'s previous closing price was ¥256, with an open of ¥257, a high of ¥258 and a low of ¥253. Trading volume was 35,300 shares as of 09/18, and trading value was ¥9.061 million. After-hours PTS data is currently unavailable for display, although after-hours trading is conducted through J-Market, operated by JapanNext Securities, and an indicator against the TSE closing price is also shown.
(2) According to the earnings report summary, revenue for the first quarter of the fiscal year ending March 2027 was approximately ¥3.66 billion, operating income was approximately ¥164 million, and net income was approximately ¥136 million, all representing significant increases from the same period of the previous year. The full-year forecast remains unchanged. The date of the next earnings announcement has not been determined.
(3) The recent performance trend and summary indicate that results have been improving over the past 12 quarters and that the equity ratio remains stable, while also pointing to profitability issues, including ROE remaining below the desirable level. Future points to monitor include increased sales in the investment and consulting businesses, growth in orders for drug discovery support, preparations for relocating the Kobe Research Institute, and the expansion of carcinogenicity testing services. The summary also identifies risk factors, including fluctuations in revenue depending on the timing of project completion, rising raw material and logistics costs, and foreign exchange movements.